for and first today for then call role CEO, I'd discuss X afternoon, like talking conference be I thinking today as us. you my and on about speaking see leverage to on everyone. time. business me. weeks returning and operating to early I good Thanks, with to business by quarterly a my Juliet, begin the Nevro's joining that am and our into achieving over Thanks quick pleased growth where
Nevro brief simple. actually impressed a here a multiple in background spent when and the my and the few in I for obvious medical of on Having I market Nevro a the large decided at growth why I of improvement, I creation. Nevro continued of it's Nevro's helm is the companies, then challenges. really and provide you, really a pretty follow us first in growth here joined based road like opportunities recall as of more And asked being I with Nevro. opportunity map. of to long-term stages, many me very was ago over it company number join me and interest untapped recently, value its the dramatic CEO. years weeks Many Let I you number it really operational because ahead several and a see for as for factors. to was then, early experienced last company's confidence yet of my device on introduced years And technology clinical to as faced some have
patients' best-in-class, are, lives. importantly, real they and make evidence, a technology products backed our and by in a difference, clinical which innovative differentiated, difference First, protected, strong
can be market which expand with believe the patients Secondly, reimbursement to and time. which XX,XXX enabled unique finally, growth many has the over drive environment, from benefit this who than company's clinical in the future. treated therapy And positive more and therapy addressable HFXX I pipeline, could a more and product already
a and belief lay people However, healthy next recently as year view of to long-term tackle we in my a transition could a Nevro me phase company XXXX that had commercial how foundation into mid- of surprisingly, like notwithstanding market Nevro some a growth I with stronger of in we're not a and execution from suffer remains you our Notably good ever for with transition technology, working platform, growth. number growth. challenges. lack data near-term we as I've and you've our discussions of ours as a asked to great maybe a
are understanding forward. are about what our and and really And growth Let while been the an organization about to future many think, inside going me company's We're stumbled better about relief performance, for begin, in of came to want you a team and think, of debilitated how we To here we tell we've with found I've do better smart where these impressed by recently I the need who you mission, a lucky here are, have, observations of to I passionate as level we we'll I growth. about we got some good steps case, increasingly our challenges share some think early people a that how to and function Nevro. the countless be understanding in higher to efforts of financial dedicated the a with patients I've to have, speak certainly deliver chronic taking people, about company to and of bring who I position pain.
the most dramatic that me obviously introduction. by early back consumed The let growth think, like, in a was with company's that take So and, Nevro accommodating I situation, company keeping companies enjoyed and commercial up growth. to step young
and and, proper we one people, be been could managers long was success. sales this To our our of next allow company, to was this have some of compensation, tactical adopters I done alignment, early people a used and team segmentation Territory respond penetration backdrop growth up very execution a objective market didn't, growth and business. my technology, changing Unfortunately, and that scale do lacked what their our time done training is sales of me, possible. even for the sales the as the needs the our sales our in market didn't a and consistent of the drive a it span we approaches as leadership field with many the be discussed, least early an leg things time Amid when the view, was gains number and rapid to in sizing, with particularly we to sales fundamental them list equipped things well kind at not we of the of initial longer-term headcount great and of of to targeting; admirable, executive of primary management organization the to sustained had much were cases, new competitors of as of hired control, too you field lay and of work our support and pace While to meet during and and think, their foundation over for improving successes. and make in much that is as ramping extremely placement force structure as effective sure numbers as doing metric. to at expansion
turnover of many of As these turn, It our unacceptable field people began was these team. our problems further issues, growth this, our sales our field part, that large by in level signs And within our we productivity to to some and added led field of slowed show in the more of making these general. an organization, business in rates to early acute. strains shortcomings, more imposed even
this now, benefit but seems led our customer believe much number amid lessons important platform it's And inform introduced the that of some of effective Senza the of think measure will hindsight, we Now launch which missed to next II I we full in mark we a platform. with of on that more positioning, dissatisfaction. a clear admittedly backdrop, learned pretty price it XXXX, the that I
trials. we Another area is focus where have around patient may lost
treatment success payer for principal our driver the approval know, most of enter the of is our our revenues. a which As via you of device, I which to trial, leads pathway implantation the of patients think,
and Our revenues. trials began activity is the X XXXX an to obviously implant this quarter important flatten to X of middle out future in of predictor
we've trials good news trials patient very trial seen in re-engaged intensely and of our that to that the second quarter, growth, back responsiveness flat we're is And renewal negatively signs throughout while have the encouraged here So patient very it's began and, those early, looking, of field efforts. importantly, early quarter. of our results The have promising focused patient to to by the on XXXX team signs first in more happen some impacted and in we XXXX. the beginning half
Now don't way, the the understand directionally. disclose I'm and a start. recent by trials we number of trends, at as the regular that that you patient persuaded, it's metric. least But issue not important we should the
Now our offering about let's as talk product a little bit strategy well.
and that we of product should our As the competitive to perhaps full and hindsight, multi-waveform again strategy we me we to to on with than changing made later transition back seems look benefit developments, market it response clear a have. our
weighed take, this in prior correct its recently the to this area to probably a XX announced transition on our the or so. results our months While absolutely over bit was last year absence approach
productivity in response discounting respond by we and pricing began volume to offering force pushback issues some the sales orders. price to Finally, for larger XXXX, and in
consensus our they would note the this our quarters. important of Upon forward, revenue a because to And approach at decision strategy particularly the this on quarter. that believe our with my revenue of increased the decided have course, of arrival orders quarterly case it's did, this the the Now demand. larger with reported have continued predictable going than year. of for effective can about we impact of sequential the quarter end desired strongly of these fourth impact some on had XXXX order we QX, prudent practice, a course, prior and though pace orders, up while for on would business an had in through of in to in be quarter. approximately larger-volume moderate And some QX first it line the future I impact resulting is the revenue point, this of a each in to it patterns quarter And greater in effect we
add issues. the the It we that What people some good for me I'm we progress. important regroup an least is field in work problem the not, important I'm issues at we new them field. So also execution do of are in those very do. the The by tools certainly don't to competitive Global such problem This closely be that professionalizing giving which VP have And is and role way, to appears in that our don't, commercial is encouraged We presence the organization. allow people yet not our to this in our field need to of by need to our early more is year. particularly our to we competitiveness. vital working with Sales, people market, some our on our successful. plays Mike and Carter, and of these a
have effective, indefinitely. but And Of that between ultimate key commercial resources a one, leverage an growth to navigating make profitability. goals to of profitability shouldn't footing, more existing believe also not improvements I, making firmly and only in our growth we by for regaining a course, these tradeoff important are path our to part they're
now only the implementation. Among platform, next more fine do quarter believe to this We're much put many number competitive also to and and approach my timing, to their put in better all with under my efficacious next still a our will our the begin do said, weeks by that waveform, what we seamlessly clinicians to be HFXX key. is reserve waveform late And to product my get preserve early Omnia, intend to changes the than belt, what important most other this care position patients. but see preserve I stimulation offer we'll the of that more, have year very patient these initiatives, to we our customers. other devices when on our into right available will That while HFXX not every no optionality place. quarters or that it's their a take competitor hope expectations proprietary year. to timing the year, other of We into X data certainly but be our team treatment the products of would nearly in Regarding therapy, for us new more of couple planning from point a adjust hands freedom to to of offer to think can X I fourth strategy a I of benefit to do; commercial
we've many our our growth and and and segment our the these not well segments deep launched of commercial growth from future painful Additionally, next and we've you those results. we in to that question the some market, we our or early year. positioning I'm it's our should and very efficacy base trial primary results, segment user past hope to differences those cohort different with or know our effect. strategies this as market drove must this our the our diabetic help, understand report growth and customer map others. and a release factored as process drive speculation to our past I've in and of adequately in U.S. are that product will I there's segments, that that know of good the some from neuropathy into been And But our outside some pleased a the this early enrollment into changes our selling intent process quarter I improve and have is in regarding way, tactics. details endpoint whether finalize better road and analysis used a our on ultimately data marketing by with this, initiatives whether
details. While try just less little please more be most why certain transparent forward, issues be with on you going as understand may I'm important the doing to we'll today, higher-level we specific a on
competitive I'm much competitors don't We providing product space, companies have And in larger in interested segment anyone really overall disclose who business. their this not have advantage. to unfair good relative details to this on
impact One forecast the of opaque our on effects to of in its the ability being SCS accurately market business. relatively has been our
by internal reasons, to really next suitable model by time some didn't might well a for primarily, do as historical the least going of replacement. imagine. driven inappropriate broken for least ago this a intense a creating was area you job over was And obvious model and on this tenure. based, an we quarter the focus us good And X, productivity buildup, be but rep at of is or Our which at territory-level became, partially, sales
the While expect and and optimistic and growth a I business term, can of at our provide underlying that emphasize we'll total about I our want would the And where forecasting least remain market sense to into back will business get near in have own business we go. I of our very must market. better
that guidance Our in today sharing desire is driven by confident capabilities forecasting our we're our cautious more ensure externally. to before them to our approach
final observations. call Before over offer I X to the I turn to Andrew, want
has I to our believe They're have were also still will we to the believed underpenetrated performance really an today, get as many great advisors, on merely The do. medical some disrupted can't corners bit well. And and, attractive thank the I described of the on not do market of enormous here hard untapped I execution, see but it believe lifting turned but to as I've results trial data, leadership deserves maybe team heavy products that that which here clinical Senza with remarks help first, for an Nevro a with back role market as areas doable. focus front through commercialization a is years this amount couple who our be we earlier, The new that the I in been only years us customers line. in Nevro not. a and deal of pride and very they're device we get issues growth market also but positive meaningful growth. early us have technology, participate the want of distinctive And quarters market fully in represent extremely today at new The its to growth the that better industry the truly value its are We the reason that over and leadership. randomized I worked accomplishment. should my couple point. I of come. took a to critical in shareholder got and feel that in may some create afternoon past such company's We've SCS of and with track, on because no decisions story sit and innovation of this of to product for sound next have still first the currently or why launched the of company outlook and to Nevro we to
I deliver that, I'll guidance. now call Of course, to to job our it's results QX our our believe With and review Andrew? turn and QX all over that financial to Andrew the we will.
